The metabolism of Amitriptyline can be decreased when combined with Terbinafine. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Norethisterone. Glimepiride may increase the hypoglycemic activities of Disopyramide. The metabolism of Dapagliflozin can be increased when combined with Nevirapine. Brimonidine may increase the antihypertensive activities of Aliskiren. The risk or severity of adverse effects can be increased when Atropine is combined with Methylscopolamine bromide. Remikiren may increase the hypotensive activities of Candesartan. The risk or severity of adverse effects can be increased when Valdecoxib is combined with Tenofovir disoproxil. The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide. Bromocriptine may increase the hypertensive activities of Formoterol. The metabolism of Amitriptyline can be decreased when combined with Felodipine. Colestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Apocynin is combined with Desonide. The risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide. The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrous oxide. The risk or severity of adverse effects can be increased when Cocaine is combined with Chloroprocaine. The metabolism of Brompheniramine can be decreased when combined with Sildenafil. Niflumic Acid may decrease the antihypertensive activities of Metipranolol. The metabolism of Prednisolone can be decreased when combined with Verapamil. Fibrinolysin may increase the anticoagulant activities of Becaplermin. Ergotamine may increase the hypertensive activities of Higenamine. The metabolism of Tazarotene can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Leflunomide is combined with Fluocortolone. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone. Palonosetron may increase the serotonergic activities of Frovatriptan. Piroxicam may decrease the antihypertensive activities of Platelet Activating Factor. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolcapone. Chlorothiazide may increase the hypotensive activities of Lofexidine. Octreotide may increase the QTc-prolonging activities of Erythromycin. The metabolism of Remoxipride can be decreased when combined with Cimetidine. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid. The metabolism of Metronidazole can be decreased when combined with Clotrimazole. The metabolism of Brompheniramine can be decreased when combined with Irbesartan. Trimazosin may increase the hypotensive activities of Amlodipine. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate. The serum concentration of Carteolol can be increased when it is combined with Cobicistat. Pseudoephedrine may increase the analgesic activities of Dextropropoxyphene. The metabolism of Ketobemidone can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levocabastine. The metabolism of Hydroxyprogesterone caproate can be increased when combined with Lumacaftor. Cabergoline may increase the hypertensive activities of Olodaterol. The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Darunavir. The serum concentration of Cyclosporine can be increased when it is combined with Lisinopril. The risk or severity of adverse effects can be increased when Docetaxel is combined with Aflibercept. The metabolism of Verapamil can be decreased when combined with Rivaroxaban. Tamsulosin may increase the hypotensive activities of Darodipine. The serum concentration of Rilpivirine can be increased when it is combined with Miconazole. The metabolism of Diclofenac can be decreased when combined with Irbesartan. The serum concentration of Cilostazol can be increased when it is combined with Ivacaftor. Indoramin may increase the hypotensive activities of Nimesulide. The risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone. Amlodipine may increase the hypotensive activities of Lercanidipine. Piroxicam may decrease the antihypertensive activities of Hydralazine. The risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol. Balsalazide may increase the anticoagulant activities of Troxerutin. The risk or severity of adverse effects can be increased when Beraprost is combined with Aloxiprin. Metipranolol may increase the hypotensive activities of Efonidipine. Amobarbital may increase the hypotensive activities of Papaverine. The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel. The risk or severity of adverse effects can be increased when Perindopril is combined with Bumetanide. The metabolism of Duloxetine can be decreased when combined with Lidocaine. Chlorzoxazone may increase the sedative activities of Pramipexole. The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Varicella Zoster Vaccine (Live/Attenuated). The metabolism of Dapagliflozin can be decreased when combined with Tolbutamide. Tarenflurbil may decrease the antihypertensive activities of Bisoprolol. The metabolism of Cinnarizine can be decreased when combined with Chlorpromazine. The serum concentration of Dasabuvir can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Cortisone acetate is combined with G17DT. The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydralazine. The metabolism of Estazolam can be decreased when combined with Sulfisoxazole. The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apremilast. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Loprazolam. The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Empagliflozin. The serum concentration of Ergotamine can be increased when it is combined with Omapatrilat. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triamcinolone. Pentobarbital may increase the hypotensive activities of Mannitol. The metabolism of Mephenytoin can be increased when combined with Secobarbital. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ezetimibe. The risk or severity of adverse effects can be increased when Quinapril is combined with Felodipine. The risk or severity of adverse effects can be increased when Ergotamine is combined with Ranitidine. The serum concentration of Difluocortolone can be increased when it is combined with Telithromycin. Magnesium Hydroxide may increase the neuromuscular blocking activities of Cisatracurium besylate. Trandolapril may increase the hypotensive activities of Phenoxybenzamine. The metabolism of Loperamide can be decreased when combined with Saquinavir. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol. The bioavailability of ME-609 can be decreased when combined with Magaldrate. The risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital. Levocabastine may increase the sedative activities of Ropinirole. The metabolism of Verapamil can be decreased when combined with Topiramate. The risk or severity of adverse effects can be increased when Iproclozide is combined with Oxycodone. Benazepril may increase the hypotensive activities of Trichlormethiazide. The therapeutic efficacy of Phenformin can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocortolone. The serum concentration of Desoximetasone can be increased when it is combined with Conjugated estrogens. The metabolism of Romidepsin can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Ketorolac is combined with Prasterone. Mizoribine may decrease the antihypertensive activities of Nadolol. Tolmetin may decrease the antihypertensive activities of Oxprenolol. The risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol. The risk or severity of adverse effects can be increased when Phenylephrine is combined with Procaterol. The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone. Furazolidone may increase the hypoglycemic activities of Sulfadiazine. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Deramciclane. The metabolism of Banoxantrone can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram. The risk or severity of adverse effects can be increased when Reserpine is combined with Pethidine. Acepromazine may increase the hypotensive activities of Betaxolol. The metabolism of Pyrazinamide can be decreased when combined with Erythromycin. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol. The serum concentration of Amoxapine can be increased when it is combined with Saxagliptin. The metabolism of Bendamustine can be decreased when combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Pheniprazine is combined with Procaterol. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Cyclizine. The serum concentration of Everolimus can be increased when it is combined with Lidocaine. The risk or severity of adverse effects can be increased when Lidocaine is combined with Norflurane. Fenbufen may decrease the antihypertensive activities of Metipranolol. The serum concentration of Methyltestosterone can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Fimasartan is combined with Ramipril. The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Desogestrel. The metabolism of Arachidonic Acid can be decreased when combined with Efavirenz. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine. The risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin. Phenobarbital may increase the hypotensive activities of Streptokinase. The metabolism of Dapsone can be decreased when combined with Lapatinib. The risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine. Lercanidipine may increase the hypotensive activities of Metoprolol. The risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluticasone propionate. The metabolism of Rosuvastatin can be decreased when combined with Imatinib.